Definition

A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor CD96 (Tactile; T-cell activation increased late expression), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nelistotug targets, binds to and inhibits CD96 expressed primarily on T cells and natural killer (NK) cells, thereby preventing its downstream signaling pathways. This may abrogate CD96-mediated inhibition of T-cell and NK cell effector function and may restore immune function and anti-tumor immune responses through the activation of T cells and NKs. This may kill and inhibit growth of tumor cells. CD96, a type I transmembrane glycoprotein of the immunoglobulin superfamily and immunological checkpoint for CD8+ T cells and NK cells, negatively regulates T-cell and NK cell activation and is overexpressed in a variety of cancer settings.